title: When is downstream pathway inhibition important?
authors.affiliation: Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
authors.forename: Sheridan
authors.initials: S
authors.lastname: Wilson
authors.affiliation: Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Electronic address: schia@bccancer.bc.ca.
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Chia
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D000068338:Everolimus; D005260:Female; D006801:Humans; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000068338:Everolimus; D020123:Sirolimus